AOD-9604 in women: what the human trial data actually shows

Last updated 2026-07-24

Does AOD-9604 work differently in women than in men?

No trial has published sex-stratified results for AOD-9604, so there's no human data saying it works better, worse, or differently in women compared to men. The drug development summaries that exist describe AOD-9604 as a modified fragment of human growth hormone (amino acids 176-191) designed to keep the fat-metabolizing activity of HGH without the growth-promoting and blood-sugar effects ^[1]. That rationale is about a mechanism, not a sex-specific one. The honest answer is: we don't know, because nobody broke the numbers out by sex in a way that's publicly available. A 2006 review of obesity drugs in clinical development covers AOD-9604 alongside other candidates from that era, and it doesn't flag any sex-based difference in response ^[2]. If you see a company claiming AOD-9604 is "better for women's stubborn fat" or anything like that, ask for the study. There isn't one.

What did the human obesity trials actually find?

This is the part that matters most, and it's the part most sellers skip. AOD-9604 went through obesity-focused clinical development, and the core problem is that the weight-loss signal did not separate convincingly from placebo. A 2004 paper in Current Opinion in Investigational Drugs, covering AOD-9604's metabolic profile, is the primary literature most often cited for this compound, and it reports on the drug's fat-metabolism activity in the context of its development program rather than showing a clean, replicated, clinically meaningful weight-loss advantage over placebo ^[1]. The 2006 review of obesity drugs then in the pipeline placed AOD-9604 among many candidates being tested for weight loss, most of which never made it to approval ^[2]. That's the pattern here. A fragment with a plausible mechanism went into trials, and the trials did not produce the kind of unambiguous separation from placebo that gets a drug to FDA approval. You can confirm this yourself: search AOD-9604 in Drugs@FDA and you'll find nothing, because it was never approved for any indication. We want to be direct about this because burying it would make this whole page useless to you. If you're a woman looking at AOD-9604 hoping for GLP-1-level or even modest-but-proven fat loss, the trial record doesn't back that up. It backs up "tested, plausible idea, didn't clear the bar."

Why did researchers think a HGH fragment would target fat specifically?

The idea behind AOD-9604 (Anti-Obesity Drug, fragment 9604) is that full-length HGH has two separate jobs baked into its structure: one region drives growth and insulin resistance, another region drives lipolysis (fat breakdown). Researchers isolated the fragment covering amino acids 176-191 hoping to get the fat-burning effect without the growth-hormone side effects like joint swelling, insulin resistance, and organ growth. That's a real and reasonable pharmacology hypothesis, and it's why AOD-9604 got taken seriously enough to reach human trials in the first place, unlike a lot of peptides sold today that never got tested in people at all. A newer 2026 review of therapeutic peptides in orthopedics discusses fragment-based and modified-peptide strategies broadly, including the logic of isolating specific growth hormone regions for targeted effects ^[3], and a 2026 Sports Medicine paper on peptide therapies for musculoskeletal injuries and athletic performance covers where the evidence for approved versus unapproved peptides currently stands ^[4]. Neither paper reports new obesity efficacy data reversing the 2004 findings. So the mechanism story is coherent. The problem isn't the biology on paper, it's that the biology on paper didn't translate into a trial result strong enough to get anyone to file for approval.

Is AOD-9604 safe for women specifically, including during pregnancy or while breastfeeding?

There is no published human safety data on AOD-9604 in pregnancy or lactation, full stop. Because it was never approved and isn't sold as a prescription drug with an FDA label, there's no pregnancy category, no lactation guidance, and no controlled safety monitoring of the kind you'd get with an approved medication. That absence of data is itself the answer: nobody has studied it in pregnant or breastfeeding women, so there's nothing to reassure you and nothing ruling it out either. If you're pregnant, trying to conceive, or breastfeeding, the responsible move is to treat it the same way you'd treat any unapproved compound with no reproductive safety data: don't use it, and talk to your OB or a physician about it if it's already come up. For general side effect patterns reported with AOD-9604 outside the reproductive-health question, see our AOD-9604 side effects page.

Does AOD-9604 affect hormones, cycles, or fertility?

There's no published human trial data measuring AOD-9604's effect on menstrual cycles, ovulation, or fertility markers. The trials that exist focused on metabolic and weight endpoints, not reproductive endocrinology ^{[1] [2]}. That means claims you might see about it being "cycle-friendly" or affecting estrogen or progesterone are not backed by anything in the literature we can point to. Because AOD-9604 is designed to avoid the insulin-resistance and growth effects of full HGH, some sellers argue it should also avoid HGH's known effects on hormone-binding proteins and other endocrine pathways. That's a reasonable-sounding inference, but it is not a finding. Nobody has run the study confirming it in women specifically.

How is AOD-9604 different from GLP-1 drugs like semaglutide for women trying to lose weight?

The honest comparison is stark: GLP-1 receptor agonists have large randomized trials with published, replicated weight-loss numbers and FDA approval; AOD-9604 has neither. If you're a woman weighing options, the comparison below reflects where each holds up as of the current public record.

This isn't a knock on wanting a peptide-based option. It's just where the evidence sits today. If you want to understand AOD-9604's full mechanism story before deciding anything, our AOD-9604 peptide overview covers that in more depth.

Is AOD-9604 legal to buy, and what does that mean for women sourcing it?

AOD-9604 is not FDA-approved, and it is not on either FDA bulks list that allows compounding pharmacies to legally use a substance in patient-specific compounded prescriptions. The two relevant lists are the 503A bulks list under 21 CFR 216.23 ^[6] and the 503B bulks list under 21 CFR 216.24 ^[7]; AOD-9604 does not appear on FDA's current nominated bulk drug substances list either ^[8]. Pharmacy compounding itself is governed by 21 U.S.C. 353a ^[9], which lays out the conditions under which a licensed pharmacist can compound a drug for an individual patient based on a valid prescription. But compounding law only applies to substances that are legally eligible bulk drug substances in the first place, and AOD-9604 sits outside that framework. Products sold as "research chemical" AOD-9604, with labels claiming "not for human consumption," are using that phrase specifically to sidestep FDA's definition of intended use under 21 CFR 201.128 ^[10], which determines whether a product is being marketed as a drug regardless of the disclaimer on the label. Practically, this means: there's no clean, approved retail channel for AOD-9604 the way there is for an FDA-approved drug. If you're going to source it at all, do it through a route with provider oversight rather than an anonymous research-chemical vendor, and go in with clear eyes about the legal gray zone you're in. AOD-9604 Co reviews provider-based sourcing options and points readers toward routes that involve pharmacy fulfillment and provider review rather than unregulated vendors; see our AOD-9604 for sale guide for what that looks like in practice.

Will AOD-9604 show up on a drug test or affect athletic eligibility for women in sport?

AOD-9604 does not interfere with the World Anti-Doping Agency's hGH isoform immunoassay, according to a 2013 study in Drug Testing and Analysis that tested this directly ^[5]. That means the specific test WADA uses to detect growth hormone doping is not thrown off by AOD-9604's presence, which matters for interpretation of test results in athletes. That is a narrow finding about one assay, not a statement that AOD-9604 is permitted in competitive sport. Separately, detection science for peptide doping has moved fast: a 2014 review in Expert Review of Proteomics covers methods for detecting peptidic drugs and their analogs in sports doping controls generally ^[11], and a 2016 method published in the Journal of Separation Science describes a technique for screening peptides under 2 kDa (AOD-9604 is a small fragment, well under that cutoff) directly from urine using liquid chromatography and ion mobility mass spectrometry ^[12]. A broader 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis covers analytical approaches for detecting emerging and non-approved drugs in human doping controls more generally ^[13]. If you compete under WADA or a similar body's rules, check your sport's prohibited list directly rather than assuming AOD-9604's non-interference with one immunoassay means it's cleared for use.

What dose have trials or reports actually used?

Public trial-level dosing detail for AOD-9604 in the peer-reviewed literature we have access to is limited, and the 2004 metabolic paper and 2006 pipeline review don't publish a granular, women-specific dosing table ^[1][2]. Reports referenced in "Gateways to clinical trials" roundups from 2003 and 2005 list AOD-9604 among compounds moving through development phases in that era, tracking its trial status rather than reporting detailed dose-response data ^[14][15][16]. What this means practically: there is no evidence-backed, trial-verified dose specifically established as optimal, let alone one validated for women versus men. Any dosing chart you see online for AOD-9604 is extrapolated from general peptide dosing conventions and anecdotal use, not from a published clinical trial's dosing arm. If you want to understand how those extrapolated protocols are typically built, see our AOD-9604 dosage guide and dosage calculator, but go in knowing the underlying number isn't trial-derived.

What are the realistic expectations for a woman considering AOD-9604 for fat loss?

Set your expectations at the level the actual trial record supports: modest at best, unproven at worst, and not something you should budget your fat-loss plan around. The core fact, worth repeating because it's the one sellers leave out, is that AOD-9604's human obesity trials did not show weight loss clearly separating from placebo ^[1][2]. That doesn't mean the fragment is dangerous or that the mechanism idea was foolish. It means the clinical trial bar, the one that separates "promising compound" from "approved medication," wasn't cleared. If you're set on trying it anyway, do it with a provider who reviews your case, sources through a legitimate pharmacy-fulfillment channel, and is honest with you about the evidence gap, rather than a storefront selling vials with a "not for human use" disclaimer stapled to a weight-loss pitch. AOD-9604 Co's role is to point you toward that provider-reviewed route rather than to oversell a compound the data doesn't support overselling. If your main goal is proven fat loss and you're comparing options, it's worth spending real time on the GLP-1 category and on basic, well-studied levers (caloric deficit, resistance training, sleep) before spending money on a compound whose own trials didn't clear placebo. For reported adverse effects across users generally, see AOD-9604 side effects, and for reconstitution mechanics if you do proceed under provider guidance, see how to reconstitute.

Frequently asked questions

Does AOD-9604 work for weight loss in women?

There's no published evidence it works differently for women specifically. The broader human obesity trials on AOD-9604 did not show weight loss that clearly separated from placebo ^[1][2], so the honest expectation for any user, regardless of sex, is modest to unproven benefit, not a reliable fat-loss effect.

Is AOD-9604 safe to use while pregnant or breastfeeding?

There's no published human safety data on AOD-9604 during pregnancy or lactation. Because it's not FDA-approved and has no reproductive safety studies, the responsible approach is to avoid it entirely during pregnancy or breastfeeding and discuss any prior use with your physician.

Does AOD-9604 affect the menstrual cycle or hormone levels?

No published trial has measured AOD-9604's effect on menstrual cycles or reproductive hormones. The existing human trials focused on metabolic and weight endpoints ^[1][2], so any claim about cycle effects is inference, not documented evidence.

Is AOD-9604 legal to buy in the US?

AOD-9604 is not FDA-approved and doesn't appear on either FDA compounding bulks list (503A under 21 CFR 216.23 ^[6] or 503B under 21 CFR 216.24 ^[7]). It's typically sold as a "research chemical" with a not-for-human-use label, which sits in a legal gray zone rather than a clearly approved retail channel.

Will AOD-9604 cause a positive doping test?

A 2013 study in Drug Testing and Analysis found AOD-9604 does not influence the WADA hGH isoform immunoassay ^[5]. That's specific to one test, not a blanket clearance for competitive use, so check your sport's prohibited substances list directly.

How does AOD-9604 compare to semaglutide or tirzepatide for women?

GLP-1 drugs like semaglutide have published, replicated weight-loss trial data and FDA approval. AOD-9604's obesity trials did not clearly separate from placebo and it has no FDA approval ^[1][2], making it a far weaker evidence position by comparison.

What is the right AOD-9604 dose for women?

There's no trial-verified dose specific to women, or to men either. Public dosing figures come from general peptide-use conventions and anecdotal reports, not from a published clinical dose-response study in the AOD-9604 literature we could locate ^{[1][2][14][15][16]}.

Can women take AOD-9604 alongside birth control or hormone therapy?

No published study examines interactions between AOD-9604 and hormonal contraceptives or hormone replacement therapy. Given the total absence of interaction data, anyone on hormonal medication should raise this specifically with a prescribing provider before combining it with AOD-9604.

Why was AOD-9604 developed as a fragment instead of using full HGH?

Researchers isolated amino acids 176-191 of human growth hormone hoping to keep the fat-metabolizing (lipolytic) activity while dropping the growth-promoting and insulin-resistance effects tied to other regions of the HGH molecule ^[1][3]. The mechanism logic was sound; it's the trial outcome that fell short of a clear win over placebo.

Did AOD-9604 ever get FDA approval for weight loss?

No. AOD-9604 does not appear in FDA's Drugs@FDA database of approved drug products, and the human obesity trial data available did not show a clear separation from placebo strong enough to support approval ^[1][2].

Are there side effects of AOD-9604 specific to women?

No published data breaks out side effects by sex. General reported effects and safety considerations are covered on our AOD-9604 side effects page; nothing in the literature identifies a female-specific adverse effect profile.

Should women use AOD-9604 for injury or joint recovery instead of fat loss?

Recent reviews (2026) discuss peptide therapies, including growth-hormone-fragment approaches, in orthopedic and musculoskeletal contexts more broadly ^[3][4], but these papers don't report AOD-9604-specific efficacy trial results for injury recovery in women. Treat this as an open question, not an established use.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): AOD-9604's metabolic/fat-metabolism findings from its development program, the primary source for its lipolytic mechanism and trial-era data
2. PubMed, Current Opinion in Investigational Drugs (2006): 2006 review of obesity drugs in clinical development, placing AOD-9604 among pipeline candidates without reporting a clear placebo-beating weight-loss effect
3. PubMed, JAAOS Global Research & Reviews (2026): Review of therapeutic peptides in orthopedics discussing fragment-based peptide strategies and mechanism rationale
4. PubMed, Sports Medicine (2026): Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
5. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence the WADA human growth hormone isoform immunoassay
6. eCFR, 21 CFR 216.23: The 503A bulk drug substances list that determines what compounding pharmacies may legally use; AOD-9604 is not on it
7. eCFR, 21 CFR 216.24: The 503B bulk drug substances list for outsourcing facilities; AOD-9604 is not on it
8. FDA, Bulk drug substances nominated for use in compounding: FDA's current nominated bulk drug substances list, which does not include AOD-9604 as an approved compounding substance
9. Cornell Law, 21 U.S.C. 353a: Federal statute governing conditions under which licensed pharmacists may compound drugs for individual patients
10. eCFR, 21 CFR 201.128: FDA's regulatory definition of intended use, relevant to 'research chemical' labeling disclaimers used to market unapproved substances
11. PubMed, Expert Review of Proteomics (2014): Review of methods for detecting peptidic drugs and analogs in sports doping controls
12. PubMed, Journal of Separation Science (2016): Method for screening peptides under 2 kDa directly from urine using liquid chromatography and ion mobility mass spectrometry
13. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Analytical approaches for detecting emerging therapeutics and non-approved drugs in human doping controls
14. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Gateways to clinical trials roundup tracking AOD-9604's development phase status in 2003
15. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Second 2003 gateways to clinical trials roundup tracking compound development status
16. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005): 2005 gateways to clinical trials roundup tracking AOD-9604's continued development status